KR20050101537A - 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제 - Google Patents
베타-아밀로이드 관련 질환의 치료를 위한 치료 제제 Download PDFInfo
- Publication number
- KR20050101537A KR20050101537A KR1020057012003A KR20057012003A KR20050101537A KR 20050101537 A KR20050101537 A KR 20050101537A KR 1020057012003 A KR1020057012003 A KR 1020057012003A KR 20057012003 A KR20057012003 A KR 20057012003A KR 20050101537 A KR20050101537 A KR 20050101537A
- Authority
- KR
- South Korea
- Prior art keywords
- agent
- amyloid
- pharmaceutical composition
- disease
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title claims abstract description 348
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title claims abstract description 348
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 224
- 201000010099 disease Diseases 0.000 title claims abstract description 191
- 238000011282 treatment Methods 0.000 title claims abstract description 113
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims description 29
- 238000009472 formulation Methods 0.000 title description 2
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 587
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 306
- 238000000034 method Methods 0.000 claims abstract description 290
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 208
- 229940126585 therapeutic drug Drugs 0.000 claims abstract description 76
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 55
- 230000007541 cellular toxicity Effects 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 156
- 150000001875 compounds Chemical class 0.000 claims description 140
- 210000004556 brain Anatomy 0.000 claims description 90
- 239000003937 drug carrier Substances 0.000 claims description 90
- 235000015872 dietary supplement Nutrition 0.000 claims description 86
- 230000015572 biosynthetic process Effects 0.000 claims description 83
- 239000002253 acid Substances 0.000 claims description 78
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims description 62
- 125000000217 alkyl group Chemical group 0.000 claims description 53
- 230000003013 cytotoxicity Effects 0.000 claims description 51
- 231100000135 cytotoxicity Toxicity 0.000 claims description 51
- 150000003839 salts Chemical class 0.000 claims description 50
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 48
- 208000024891 symptom Diseases 0.000 claims description 47
- 229940079593 drug Drugs 0.000 claims description 46
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 45
- 239000001257 hydrogen Substances 0.000 claims description 44
- 229910052739 hydrogen Inorganic materials 0.000 claims description 44
- 230000003941 amyloidogenesis Effects 0.000 claims description 41
- 206010012289 Dementia Diseases 0.000 claims description 38
- 208000010877 cognitive disease Diseases 0.000 claims description 38
- 150000002148 esters Chemical class 0.000 claims description 38
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 36
- 230000003920 cognitive function Effects 0.000 claims description 35
- 230000000694 effects Effects 0.000 claims description 35
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims description 33
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims description 33
- 238000000151 deposition Methods 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 32
- 208000035475 disorder Diseases 0.000 claims description 32
- 230000008021 deposition Effects 0.000 claims description 29
- 230000002265 prevention Effects 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 28
- 229910052757 nitrogen Inorganic materials 0.000 claims description 28
- 238000002560 therapeutic procedure Methods 0.000 claims description 26
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims description 25
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims description 24
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 24
- 229960004373 acetylcholine Drugs 0.000 claims description 24
- 230000002401 inhibitory effect Effects 0.000 claims description 24
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 23
- 230000006933 amyloid-beta aggregation Effects 0.000 claims description 22
- 230000003993 interaction Effects 0.000 claims description 22
- 229940124597 therapeutic agent Drugs 0.000 claims description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 21
- 208000037259 Amyloid Plaque Diseases 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- LZXHHNKULPHARO-UHFFFAOYSA-M (3,4-dichlorophenyl)methyl-triphenylphosphanium;chloride Chemical group [Cl-].C1=C(Cl)C(Cl)=CC=C1C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 LZXHHNKULPHARO-UHFFFAOYSA-M 0.000 claims description 19
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Amino-1-propanesulfonic acid Natural products NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 210000002469 basement membrane Anatomy 0.000 claims description 19
- 229940024606 amino acid Drugs 0.000 claims description 18
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 17
- 125000000623 heterocyclic group Chemical group 0.000 claims description 17
- 208000002780 macular degeneration Diseases 0.000 claims description 17
- 150000001408 amides Chemical class 0.000 claims description 16
- 239000003112 inhibitor Substances 0.000 claims description 16
- 230000015556 catabolic process Effects 0.000 claims description 15
- 102100033639 Acetylcholinesterase Human genes 0.000 claims description 14
- 108010022752 Acetylcholinesterase Proteins 0.000 claims description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 14
- 102000016611 Proteoglycans Human genes 0.000 claims description 14
- 108010067787 Proteoglycans Proteins 0.000 claims description 14
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 14
- 238000006731 degradation reaction Methods 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 102000003886 Glycoproteins Human genes 0.000 claims description 13
- 125000002091 cationic group Chemical group 0.000 claims description 13
- 230000001771 impaired effect Effects 0.000 claims description 13
- 230000015654 memory Effects 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 13
- 206010061218 Inflammation Diseases 0.000 claims description 12
- 230000006735 deficit Effects 0.000 claims description 12
- 230000002068 genetic effect Effects 0.000 claims description 12
- 230000004054 inflammatory process Effects 0.000 claims description 12
- 201000010374 Down Syndrome Diseases 0.000 claims description 11
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 11
- 239000000935 antidepressant agent Substances 0.000 claims description 11
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 11
- 238000001727 in vivo Methods 0.000 claims description 11
- 210000002569 neuron Anatomy 0.000 claims description 11
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 10
- 206010029350 Neurotoxicity Diseases 0.000 claims description 10
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 10
- 201000004810 Vascular dementia Diseases 0.000 claims description 10
- 229940022698 acetylcholinesterase Drugs 0.000 claims description 10
- 125000003277 amino group Chemical group 0.000 claims description 10
- 229940005513 antidepressants Drugs 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 235000006708 antioxidants Nutrition 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 10
- 150000001768 cations Chemical class 0.000 claims description 10
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 10
- 231100000228 neurotoxicity Toxicity 0.000 claims description 10
- 230000007135 neurotoxicity Effects 0.000 claims description 10
- 230000008506 pathogenesis Effects 0.000 claims description 10
- 231100000419 toxicity Toxicity 0.000 claims description 10
- 208000000044 Amnesia Diseases 0.000 claims description 9
- 108010058699 Choline O-acetyltransferase Proteins 0.000 claims description 9
- 102100023460 Choline O-acetyltransferase Human genes 0.000 claims description 9
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims description 9
- 208000028698 Cognitive impairment Diseases 0.000 claims description 9
- 108090000288 Glycoproteins Proteins 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- 230000003542 behavioural effect Effects 0.000 claims description 9
- 230000031018 biological processes and functions Effects 0.000 claims description 9
- 229940088598 enzyme Drugs 0.000 claims description 9
- 239000000835 fiber Substances 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 229960001685 tacrine Drugs 0.000 claims description 9
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical group C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims description 9
- 208000026139 Memory disease Diseases 0.000 claims description 8
- 229960001231 choline Drugs 0.000 claims description 8
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- 229960004640 memantine Drugs 0.000 claims description 8
- 210000000274 microglia Anatomy 0.000 claims description 8
- 230000000926 neurological effect Effects 0.000 claims description 8
- 230000002335 preservative effect Effects 0.000 claims description 8
- 208000019901 Anxiety disease Diseases 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 206010018985 Haemorrhage intracranial Diseases 0.000 claims description 7
- 208000008574 Intracranial Hemorrhages Diseases 0.000 claims description 7
- 206010039966 Senile dementia Diseases 0.000 claims description 7
- 208000006011 Stroke Diseases 0.000 claims description 7
- 208000027418 Wounds and injury Diseases 0.000 claims description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 7
- 230000004913 activation Effects 0.000 claims description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims description 7
- 230000003942 amyloidogenic effect Effects 0.000 claims description 7
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- 201000008319 inclusion body myositis Diseases 0.000 claims description 7
- 230000006984 memory degeneration Effects 0.000 claims description 7
- 208000023060 memory loss Diseases 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 7
- 230000026731 phosphorylation Effects 0.000 claims description 7
- 238000006366 phosphorylation reaction Methods 0.000 claims description 7
- 238000012545 processing Methods 0.000 claims description 7
- 229910052725 zinc Inorganic materials 0.000 claims description 7
- 239000011701 zinc Substances 0.000 claims description 7
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical group [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 6
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 6
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 6
- 230000001430 anti-depressive effect Effects 0.000 claims description 6
- 201000007201 aphasia Diseases 0.000 claims description 6
- 230000005779 cell damage Effects 0.000 claims description 6
- 208000037887 cell injury Diseases 0.000 claims description 6
- 210000003169 central nervous system Anatomy 0.000 claims description 6
- 229910052802 copper Inorganic materials 0.000 claims description 6
- 239000010949 copper Substances 0.000 claims description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical group C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 6
- 239000000262 estrogen Substances 0.000 claims description 6
- 229940011871 estrogen Drugs 0.000 claims description 6
- 230000004761 fibrosis Effects 0.000 claims description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 238000011321 prophylaxis Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 5
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 206010029240 Neuritis Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 108010050254 Presenilins Proteins 0.000 claims description 5
- 208000028017 Psychotic disease Diseases 0.000 claims description 5
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 5
- 230000000434 anti-fibrogenic effect Effects 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 230000006399 behavior Effects 0.000 claims description 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 5
- 230000001976 improved effect Effects 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 239000000787 lecithin Substances 0.000 claims description 5
- 235000010445 lecithin Nutrition 0.000 claims description 5
- 229940067606 lecithin Drugs 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 239000002243 precursor Substances 0.000 claims description 5
- 239000004089 psychotropic agent Substances 0.000 claims description 5
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical group C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 5
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 108050005851 Amyloidogenic glycoproteins Proteins 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010010904 Convulsion Diseases 0.000 claims description 4
- 206010012239 Delusion Diseases 0.000 claims description 4
- 206010064571 Gene mutation Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 108091000080 Phosphotransferase Proteins 0.000 claims description 4
- RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical group CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 101150031224 app gene Proteins 0.000 claims description 4
- 230000037007 arousal Effects 0.000 claims description 4
- 125000005199 aryl carbonyloxy group Chemical group 0.000 claims description 4
- 125000005110 aryl thio group Chemical group 0.000 claims description 4
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 claims description 4
- 125000001246 bromo group Chemical group Br* 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 231100000868 delusion Toxicity 0.000 claims description 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
- 229960003980 galantamine Drugs 0.000 claims description 4
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 4
- 230000006951 hyperphosphorylation Effects 0.000 claims description 4
- 208000034783 hypoesthesia Diseases 0.000 claims description 4
- 208000003532 hypothyroidism Diseases 0.000 claims description 4
- 230000002989 hypothyroidism Effects 0.000 claims description 4
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical group COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 claims description 4
- 229960004135 idebenone Drugs 0.000 claims description 4
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 claims description 4
- 229910021645 metal ion Inorganic materials 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 230000000324 neuroprotective effect Effects 0.000 claims description 4
- 231100000862 numbness Toxicity 0.000 claims description 4
- 102000020233 phosphotransferase Human genes 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 229960002934 propentofylline Drugs 0.000 claims description 4
- 229940001470 psychoactive drug Drugs 0.000 claims description 4
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 4
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 4
- 229960003946 selegiline Drugs 0.000 claims description 4
- 208000019116 sleep disease Diseases 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 206010042772 syncope Diseases 0.000 claims description 4
- 238000013519 translation Methods 0.000 claims description 4
- 238000012384 transportation and delivery Methods 0.000 claims description 4
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 3
- LFWHFZJPXXOYNR-RQZCQDPDSA-N 2-[(3e)-6-fluoro-2-methyl-3-[(4-methylsulfanylphenyl)methylidene]inden-1-yl]acetic acid Chemical compound C1=CC(SC)=CC=C1\C=C/1C2=CC=C(F)C=C2C(CC(O)=O)=C\1C LFWHFZJPXXOYNR-RQZCQDPDSA-N 0.000 claims description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 3
- 201000004569 Blindness Diseases 0.000 claims description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical group C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 claims description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 3
- 206010017577 Gait disturbance Diseases 0.000 claims description 3
- 244000194101 Ginkgo biloba Species 0.000 claims description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 3
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims description 3
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims description 3
- 208000004547 Hallucinations Diseases 0.000 claims description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 3
- 206010022998 Irritability Diseases 0.000 claims description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 3
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 3
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims description 3
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims description 3
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical group CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims description 3
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 229940087168 alpha tocopherol Drugs 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 230000000561 anti-psychotic effect Effects 0.000 claims description 3
- 239000002948 appetite stimulant Substances 0.000 claims description 3
- 229940039856 aricept Drugs 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 239000002439 beta secretase inhibitor Substances 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 229960005228 clioquinol Drugs 0.000 claims description 3
- 229940109262 curcumin Drugs 0.000 claims description 3
- 235000012754 curcumin Nutrition 0.000 claims description 3
- 239000004148 curcumin Substances 0.000 claims description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 3
- 238000009826 distribution Methods 0.000 claims description 3
- 229940108366 exelon Drugs 0.000 claims description 3
- 239000003540 gamma secretase inhibitor Substances 0.000 claims description 3
- 239000003163 gonadal steroid hormone Substances 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 229960001680 ibuprofen Drugs 0.000 claims description 3
- 150000002475 indoles Chemical class 0.000 claims description 3
- 229960000905 indomethacin Drugs 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 3
- 229960003987 melatonin Drugs 0.000 claims description 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 239000003176 neuroleptic agent Substances 0.000 claims description 3
- 230000000701 neuroleptic effect Effects 0.000 claims description 3
- 239000004090 neuroprotective agent Substances 0.000 claims description 3
- 201000003077 normal pressure hydrocephalus Diseases 0.000 claims description 3
- 238000006384 oligomerization reaction Methods 0.000 claims description 3
- 230000004792 oxidative damage Effects 0.000 claims description 3
- 229960001697 physostigmine Drugs 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 239000000583 progesterone congener Substances 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 229960004136 rivastigmine Drugs 0.000 claims description 3
- 229960000984 tocofersolan Drugs 0.000 claims description 3
- 230000001052 transient effect Effects 0.000 claims description 3
- 230000004393 visual impairment Effects 0.000 claims description 3
- 208000016261 weight loss Diseases 0.000 claims description 3
- 230000004580 weight loss Effects 0.000 claims description 3
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical group C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 claims description 3
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 claims description 3
- 235000004835 α-tocopherol Nutrition 0.000 claims description 3
- 239000002076 α-tocopherol Substances 0.000 claims description 3
- 101150037123 APOE gene Proteins 0.000 claims description 2
- 208000002667 Subdural Hematoma Diseases 0.000 claims description 2
- 239000008240 homogeneous mixture Substances 0.000 claims description 2
- 238000002657 hormone replacement therapy Methods 0.000 claims description 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 2
- 229910001867 inorganic solvent Inorganic materials 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000013522 chelant Substances 0.000 claims 10
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical group C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 8
- GOLXRNDWAUTYKT-UHFFFAOYSA-N 3-(1H-indol-3-yl)propanoic acid Chemical group C1=CC=C2C(CCC(=O)O)=CNC2=C1 GOLXRNDWAUTYKT-UHFFFAOYSA-N 0.000 claims 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 2
- QYIMSPSDBYKPPY-BANQPHDMSA-N 2,3-epoxysqualene Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC1OC1(C)C QYIMSPSDBYKPPY-BANQPHDMSA-N 0.000 claims 2
- WAWDOEHEAULMGC-UHFFFAOYSA-N 3-[(6-butoxypyridin-3-yl)diazenyl]pyridine-2,6-diamine Chemical compound C1=NC(OCCCC)=CC=C1N=NC1=CC=C(N)N=C1N WAWDOEHEAULMGC-UHFFFAOYSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 229940122578 Acetylcholine receptor agonist Drugs 0.000 claims 2
- 206010002091 Anaesthesia Diseases 0.000 claims 2
- 241000516950 Atheroides Species 0.000 claims 2
- 239000005711 Benzoic acid Substances 0.000 claims 2
- 229940123923 Butyrylcholinesterase inhibitor Drugs 0.000 claims 2
- 206010012374 Depressed mood Diseases 0.000 claims 2
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 claims 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims 2
- 208000004044 Hypesthesia Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 206010021639 Incontinence Diseases 0.000 claims 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical group OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 2
- 208000016285 Movement disease Diseases 0.000 claims 2
- 229940095474 NMDA agonist Drugs 0.000 claims 2
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 2
- 229940122907 Phosphatase inhibitor Drugs 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 2
- 208000024571 Pick disease Diseases 0.000 claims 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 2
- 206010040030 Sensory loss Diseases 0.000 claims 2
- 206010041243 Social avoidant behaviour Diseases 0.000 claims 2
- 206010042458 Suicidal ideation Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 229940122803 Vinca alkaloid Drugs 0.000 claims 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 2
- 229930003779 Vitamin B12 Natural products 0.000 claims 2
- 229930003427 Vitamin E Natural products 0.000 claims 2
- AKZWRTCWNXHHFR-PDIZUQLASA-N [(3S)-oxolan-3-yl] N-[(2S,3S)-4-[(5S)-5-benzyl-3-[(2R)-2-carbamoyloxy-2,3-dihydro-1H-inden-1-yl]-4-oxo-3H-pyrrol-5-yl]-3-hydroxy-1-phenylbutan-2-yl]carbamate Chemical group NC(=O)O[C@@H]1Cc2ccccc2C1C1C=N[C@](C[C@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@H]2CCOC2)(Cc2ccccc2)C1=O AKZWRTCWNXHHFR-PDIZUQLASA-N 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 2
- 230000037005 anaesthesia Effects 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 235000010233 benzoic acid Nutrition 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 150000001576 beta-amino acids Chemical group 0.000 claims 2
- 238000004140 cleaning Methods 0.000 claims 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 2
- 229960003133 ergot alkaloid Drugs 0.000 claims 2
- KMJTTWREVXZPTK-UHFFFAOYSA-N ethyl(methyl)carbamic acid Chemical compound CCN(C)C(O)=O KMJTTWREVXZPTK-UHFFFAOYSA-N 0.000 claims 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 2
- 230000001146 hypoxic effect Effects 0.000 claims 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 2
- 239000003290 indole 3-propionic acid Substances 0.000 claims 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 210000004558 lewy body Anatomy 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 2
- 239000003706 n methyl dextro aspartic acid receptor stimulating agent Substances 0.000 claims 2
- 230000000508 neurotrophic effect Effects 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 239000011574 phosphorus Substances 0.000 claims 2
- MICLTPPSCUXHJT-UHFFFAOYSA-M potassium;4-[3-(6-oxo-3h-purin-9-yl)propanoylamino]benzoate Chemical compound [K+].C1=CC(C(=O)[O-])=CC=C1NC(=O)CCN1C(NC=NC2=O)=C2N=C1 MICLTPPSCUXHJT-UHFFFAOYSA-M 0.000 claims 2
- 239000003642 reactive oxygen metabolite Substances 0.000 claims 2
- 125000004436 sodium atom Chemical group 0.000 claims 2
- 230000003637 steroidlike Effects 0.000 claims 2
- 230000016978 synaptic transmission, cholinergic Effects 0.000 claims 2
- 235000019155 vitamin A Nutrition 0.000 claims 2
- 239000011719 vitamin A Substances 0.000 claims 2
- 235000019163 vitamin B12 Nutrition 0.000 claims 2
- 239000011715 vitamin B12 Substances 0.000 claims 2
- 235000019165 vitamin E Nutrition 0.000 claims 2
- 239000011709 vitamin E Substances 0.000 claims 2
- 229940046009 vitamin E Drugs 0.000 claims 2
- 229940045997 vitamin a Drugs 0.000 claims 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 claims 1
- 206010018852 Haematoma Diseases 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- 238000011278 co-treatment Methods 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 229930002330 retinoic acid Natural products 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 229960001727 tretinoin Drugs 0.000 claims 1
- 230000000050 nutritive effect Effects 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 38
- 238000005755 formation reaction Methods 0.000 description 38
- 206010002022 amyloidosis Diseases 0.000 description 27
- 150000007513 acids Chemical class 0.000 description 21
- 125000003342 alkenyl group Chemical group 0.000 description 20
- 230000007423 decrease Effects 0.000 description 19
- 230000006870 function Effects 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 19
- 125000000304 alkynyl group Chemical group 0.000 description 17
- 230000007246 mechanism Effects 0.000 description 17
- 229910052760 oxygen Inorganic materials 0.000 description 17
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 16
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 16
- 239000001301 oxygen Substances 0.000 description 16
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 16
- 125000001425 triazolyl group Chemical group 0.000 description 16
- 230000009471 action Effects 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- 125000005358 mercaptoalkyl group Chemical group 0.000 description 15
- 125000000335 thiazolyl group Chemical group 0.000 description 15
- 230000004071 biological effect Effects 0.000 description 14
- 230000035772 mutation Effects 0.000 description 14
- 125000002883 imidazolyl group Chemical group 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 108010026424 tau Proteins Proteins 0.000 description 12
- 102000013498 tau Proteins Human genes 0.000 description 12
- 102000013918 Apolipoproteins E Human genes 0.000 description 11
- 108010025628 Apolipoproteins E Proteins 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- 230000007170 pathology Effects 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 10
- 150000002367 halogens Chemical class 0.000 description 10
- 239000002858 neurotransmitter agent Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 125000003831 tetrazolyl group Chemical group 0.000 description 10
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 9
- 230000001149 cognitive effect Effects 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 230000000750 progressive effect Effects 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 208000012902 Nervous system disease Diseases 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 8
- 210000002932 cholinergic neuron Anatomy 0.000 description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 208000025966 Neurological disease Diseases 0.000 description 7
- 102100022033 Presenilin-1 Human genes 0.000 description 7
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000006999 cognitive decline Effects 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229940076279 serotonin Drugs 0.000 description 7
- 102100032404 Cholinesterase Human genes 0.000 description 6
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 6
- 229920002971 Heparan sulfate Polymers 0.000 description 6
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 6
- 108090000054 Syndecan-2 Proteins 0.000 description 6
- 238000001994 activation Methods 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000002738 chelating agent Substances 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 230000007850 degeneration Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 208000015756 familial Alzheimer disease Diseases 0.000 description 6
- 206010027175 memory impairment Diseases 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 5
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 5
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 5
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 102000010909 Monoamine Oxidase Human genes 0.000 description 5
- 108010062431 Monoamine oxidase Proteins 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 5
- 125000005129 aryl carbonyl group Chemical group 0.000 description 5
- 230000008499 blood brain barrier function Effects 0.000 description 5
- 210000001218 blood-brain barrier Anatomy 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000019771 cognition Effects 0.000 description 5
- 238000011262 co‐therapy Methods 0.000 description 5
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000013016 learning Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 229960002296 paroxetine Drugs 0.000 description 5
- 239000008024 pharmaceutical diluent Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 239000008020 pharmaceutical preservative Substances 0.000 description 5
- 229940127557 pharmaceutical product Drugs 0.000 description 5
- 208000020016 psychiatric disease Diseases 0.000 description 5
- 229940044601 receptor agonist Drugs 0.000 description 5
- 239000000018 receptor agonist Substances 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 4
- 108010053652 Butyrylcholinesterase Proteins 0.000 description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108090000322 Cholinesterases Proteins 0.000 description 4
- 238000008214 LDL Cholesterol Methods 0.000 description 4
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 4
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 4
- 108090000315 Protein Kinase C Proteins 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 239000001961 anticonvulsive agent Substances 0.000 description 4
- 239000002249 anxiolytic agent Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000000480 calcium channel blocker Substances 0.000 description 4
- 125000002837 carbocyclic group Chemical group 0.000 description 4
- 230000001713 cholinergic effect Effects 0.000 description 4
- 229960001653 citalopram Drugs 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 4
- 230000007278 cognition impairment Effects 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000001087 myotubule Anatomy 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 229960005017 olanzapine Drugs 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 4
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 4
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 3
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 3
- 108010036933 Presenilin-1 Proteins 0.000 description 3
- 102100022036 Presenilin-2 Human genes 0.000 description 3
- 102000015499 Presenilins Human genes 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000007450 amyloidogenic pathway Effects 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- 150000001557 benzodiazepines Chemical class 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229960003120 clonazepam Drugs 0.000 description 3
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 3
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229960002464 fluoxetine Drugs 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 3
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 3
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 3
- 238000002610 neuroimaging Methods 0.000 description 3
- 229960001158 nortriptyline Drugs 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 210000004129 prosencephalon Anatomy 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 229960001534 risperidone Drugs 0.000 description 3
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 3
- 229940121356 serotonin receptor antagonist Drugs 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 229940083542 sodium Drugs 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 3
- 229960000607 ziprasidone Drugs 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- KYZWKYWGQFCRGN-OASOTCBPSA-N (2s)-2-aminopentanedioic acid;(2r)-2-(methylamino)butanedioic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O.OC(=O)[C@@H](N)CCC(O)=O KYZWKYWGQFCRGN-OASOTCBPSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 2
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 102000001049 Amyloid Human genes 0.000 description 2
- 108010094108 Amyloid Proteins 0.000 description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
- 102100029470 Apolipoprotein E Human genes 0.000 description 2
- 101710095339 Apolipoprotein E Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 2
- 230000007082 Aβ accumulation Effects 0.000 description 2
- 201000000166 CST3-related cerebral amyloid angiopathy Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 description 2
- 102000003914 Cholinesterases Human genes 0.000 description 2
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 2
- 102400000124 Cyclin-dependent kinase 5 activator 1, p35 Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000012239 Developmental disease Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 208000036626 Mental retardation Diseases 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- 102400001357 Motilin Human genes 0.000 description 2
- 101800002372 Motilin Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- RXBKMJIPNDOHFR-UHFFFAOYSA-N Phenelzine sulfate Chemical compound OS(O)(=O)=O.NNCCC1=CC=CC=C1 RXBKMJIPNDOHFR-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108010036908 Presenilin-2 Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000027520 Somatoform disease Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- BKPRVQDIOGQWTG-ICOOEGOYSA-N [(1s,2r)-2-phenylcyclopropyl]azanium;[(1r,2s)-2-phenylcyclopropyl]azanium;sulfate Chemical compound [O-]S([O-])(=O)=O.[NH3+][C@H]1C[C@@H]1C1=CC=CC=C1.[NH3+][C@@H]1C[C@H]1C1=CC=CC=C1 BKPRVQDIOGQWTG-ICOOEGOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 125000006323 alkenyl amino group Chemical group 0.000 description 2
- 125000005108 alkenylthio group Chemical group 0.000 description 2
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 229940025141 anafranil Drugs 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940035678 anti-parkinson drug Drugs 0.000 description 2
- 229940125713 antianxiety drug Drugs 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229960004676 antithrombotic agent Drugs 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000006741 behavioral dysfunction Effects 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 2
- 229960001058 bupropion Drugs 0.000 description 2
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229940047493 celexa Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000009920 chelation Effects 0.000 description 2
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 229940068796 clozaril Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 229960000958 deferoxamine Drugs 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 125000004986 diarylamino group Chemical group 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 208000018459 dissociative disease Diseases 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 229940098766 effexor Drugs 0.000 description 2
- 229940011681 elavil Drugs 0.000 description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000003825 glutamate receptor antagonist Substances 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 231100000863 loss of memory Toxicity 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000002715 modification method Methods 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 239000000472 muscarinic agonist Substances 0.000 description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 2
- 229940087524 nardil Drugs 0.000 description 2
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 2
- 229960001800 nefazodone Drugs 0.000 description 2
- DYCKFEBIOUQECE-UHFFFAOYSA-N nefazodone hydrochloride Chemical compound [H+].[Cl-].O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 DYCKFEBIOUQECE-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 229940087824 parnate Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 208000022821 personality disease Diseases 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 238000013439 planning Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 2
- 229940035613 prozac Drugs 0.000 description 2
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 2
- 229960004431 quetiapine Drugs 0.000 description 2
- ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 229940023942 remeron Drugs 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229940035004 seroquel Drugs 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 229960002073 sertraline Drugs 0.000 description 2
- 229940099190 serzone Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 231100000736 substance abuse Toxicity 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 229940118176 surmontil Drugs 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000005495 thyroid hormone Substances 0.000 description 2
- 229940036555 thyroid hormone Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229940041597 tofranil Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229960003991 trazodone Drugs 0.000 description 2
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 2
- YDGHCKHAXOUQOS-BTJKTKAUSA-N trimipramine maleate Chemical compound [O-]C(=O)\C=C/C([O-])=O.C1CC2=CC=CC=C2[NH+](CC(C[NH+](C)C)C)C2=CC=CC=C21 YDGHCKHAXOUQOS-BTJKTKAUSA-N 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000006441 vascular event Effects 0.000 description 2
- 229960004688 venlafaxine Drugs 0.000 description 2
- 229960000744 vinpocetine Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940020965 zoloft Drugs 0.000 description 2
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 2
- 229940039925 zyprexa Drugs 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ZVWHURINXJWEER-UHFFFAOYSA-N 1,1,3,3-tetraphenylurea Chemical compound C=1C=CC=CC=1N(C=1C=CC=CC=1)C(=O)N(C=1C=CC=CC=1)C1=CC=CC=C1 ZVWHURINXJWEER-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- GRUVVLWKPGIYEG-UHFFFAOYSA-N 2-[2-[carboxymethyl-[(2-hydroxyphenyl)methyl]amino]ethyl-[(2-hydroxyphenyl)methyl]amino]acetic acid Chemical compound C=1C=CC=C(O)C=1CN(CC(=O)O)CCN(CC(O)=O)CC1=CC=CC=C1O GRUVVLWKPGIYEG-UHFFFAOYSA-N 0.000 description 1
- 125000003816 2-hydroxybenzoyl group Chemical group OC1=C(C(=O)*)C=CC=C1 0.000 description 1
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 1
- DCJAWPYJSRHQRN-UHFFFAOYSA-N 3-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)propanoic acid Chemical compound CC1=C(O)C(=O)C=CN1CCC(O)=O DCJAWPYJSRHQRN-UHFFFAOYSA-N 0.000 description 1
- DSIHEWRAJBNNLQ-UHFFFAOYSA-N 3-(4-phenyl-3,6-dihydro-2h-pyridin-1-yl)propane-1-sulfonic acid Chemical compound C1N(CCCS(=O)(=O)O)CCC(C=2C=CC=CC=2)=C1 DSIHEWRAJBNNLQ-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- ALVDRCWCXLKMLE-UHFFFAOYSA-N 5-(hydroxymethyl)-2-methyl-4-[(pyridin-4-ylmethylhydrazinylidene)methyl]pyridin-3-ol Chemical compound Cc1ncc(CO)c(C=NNCc2ccncc2)c1O ALVDRCWCXLKMLE-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- SFIUYASDNWEYDB-HHQFNNIRSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;(2s)-1-[(2s)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O.C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O SFIUYASDNWEYDB-HHQFNNIRSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HLVVITIHAZBPKB-UHFFFAOYSA-N 9-amino-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C1=CC=C2C(N)=C(C(O)CCC3)C3=NC2=C1 HLVVITIHAZBPKB-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 208000024667 ABeta amyloidosis, Dutch type Diseases 0.000 description 1
- 208000023697 ABri amyloidosis Diseases 0.000 description 1
- 208000017227 ADan amyloidosis Diseases 0.000 description 1
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 102000018430 Amyloid-beta precursor proteins Human genes 0.000 description 1
- 108050007552 Amyloid-beta precursor proteins Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
- 102100021257 Beta-secretase 1 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- RKLNONIVDFXQRX-UHFFFAOYSA-N Bromperidol Chemical compound C1CC(O)(C=2C=CC(Br)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 RKLNONIVDFXQRX-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101150053721 Cdk5 gene Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 101100385253 Chiloscyllium indicum GM1 gene Proteins 0.000 description 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108091007403 Cholesterol transporters Proteins 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 208000022540 Consciousness disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- UBAPRWGDQPSCEH-UHFFFAOYSA-N Des-N-methyl-beta-obscurine Natural products N1CCCC2C3CC(C)CC21C(C=CC(=O)N1)=C1C3 UBAPRWGDQPSCEH-UHFFFAOYSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- WYJAPUKIYAZSEM-MOPGFXCFSA-N Eburnamonine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)CC(=O)N5C2=C1 WYJAPUKIYAZSEM-MOPGFXCFSA-N 0.000 description 1
- VWLHWLSRQJQWRG-UHFFFAOYSA-O Edrophonum Chemical compound CC[N+](C)(C)C1=CC=CC(O)=C1 VWLHWLSRQJQWRG-UHFFFAOYSA-O 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 108010061075 Enterobactin Proteins 0.000 description 1
- SERBHKJMVBATSJ-UHFFFAOYSA-N Enterobactin Natural products OC1=CC=CC(C(=O)NC2C(OCC(C(=O)OCC(C(=O)OC2)NC(=O)C=2C(=C(O)C=CC=2)O)NC(=O)C=2C(=C(O)C=CC=2)O)=O)=C1O SERBHKJMVBATSJ-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 206010053487 Exposure to toxic agent Diseases 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 208000026097 Factitious disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 1
- 102000004878 Gelsolin Human genes 0.000 description 1
- 108090001064 Gelsolin Proteins 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 229940122459 Glutamate antagonist Drugs 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 1
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 1
- YYWGABLTRMRUIT-XHBSWPGZSA-N Huperzine B Natural products N1CCC[C@@H]2[C@@H]3C=C(C)C[C@]21C(C=CC(=O)N1)=C1C3 YYWGABLTRMRUIT-XHBSWPGZSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 description 1
- 201000000194 ITM2B-related cerebral amyloid angiopathy 2 Diseases 0.000 description 1
- MADRVGBADLFHMO-UHFFFAOYSA-N Indeloxazine Chemical compound C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 MADRVGBADLFHMO-UHFFFAOYSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- 101710202113 Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
- 206010052276 Pseudodementia Diseases 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 208000030451 Vascular dementia disease Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- RRGMXBQMCUKRLH-CTNGQTDRSA-N [(3ar,8bs)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] n-heptylcarbamate Chemical compound C12=CC(OC(=O)NCCCCCCC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C RRGMXBQMCUKRLH-CTNGQTDRSA-N 0.000 description 1
- PBHFNBQPZCRWQP-QUCCMNQESA-N [(3ar,8bs)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] n-phenylcarbamate Chemical compound CN([C@@H]1[C@@](C2=C3)(C)CCN1C)C2=CC=C3OC(=O)NC1=CC=CC=C1 PBHFNBQPZCRWQP-QUCCMNQESA-N 0.000 description 1
- FZSPJBYOKQPKCD-VIFPVBQESA-N [1-(4-chlorophenyl)-2-methylpropan-2-yl] (2s)-2-aminopropanoate Chemical compound C[C@H](N)C(=O)OC(C)(C)CC1=CC=C(Cl)C=C1 FZSPJBYOKQPKCD-VIFPVBQESA-N 0.000 description 1
- 229940056213 abilify Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 230000007000 age related cognitive decline Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 229960003225 alaproclate Drugs 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 229940094070 ambien Drugs 0.000 description 1
- OYTKINVCDFNREN-UHFFFAOYSA-N amifampridine Chemical compound NC1=CC=NC=C1N OYTKINVCDFNREN-UHFFFAOYSA-N 0.000 description 1
- 229960004012 amifampridine Drugs 0.000 description 1
- 239000003194 amino acid receptor blocking agent Substances 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940089918 ansaid Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000676 anti-immunogenic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940053482 antidepressant drug mao a inhibitors Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002255 antigout agent Substances 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 229940082988 antihypertensives serotonin antagonists Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
- 125000004350 aryl cycloalkyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940072698 ativan Drugs 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- CPFJLLXFNPCTDW-BWSPSPBFSA-N benzatropine mesylate Chemical compound CS([O-])(=O)=O.O([C@H]1C[C@H]2CC[C@@H](C1)[NH+]2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 CPFJLLXFNPCTDW-BWSPSPBFSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940125690 blood glucose regulator Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 208000025698 brain inflammatory disease Diseases 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229960004037 bromperidol Drugs 0.000 description 1
- 229940015273 buspar Drugs 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940097633 capoten Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000001269 cardiogenic effect Effects 0.000 description 1
- 229940045200 cardioprotective agent Drugs 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 201000004559 cerebral degeneration Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- PBKVEOSEPXMKDN-LZHUFOCISA-N chembl2311030 Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)CC)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 PBKVEOSEPXMKDN-LZHUFOCISA-N 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000031154 cholesterol homeostasis Effects 0.000 description 1
- 229960002688 choline salicylate Drugs 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940097480 cogentin Drugs 0.000 description 1
- 231100000876 cognitive deterioration Toxicity 0.000 description 1
- 239000002475 cognitive enhancer Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 208000030251 communication disease Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229960000729 cyclandelate Drugs 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 229940005501 dopaminergic agent Drugs 0.000 description 1
- 229940052764 dopaminergic anti-parkinson drug mao b inhibitors Drugs 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000036536 dutch type ABeta amyloidosis Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229950007919 egtazic acid Drugs 0.000 description 1
- 229940084238 eldepryl Drugs 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- SERBHKJMVBATSJ-BZSNNMDCSA-N enterobactin Chemical compound OC1=CC=CC(C(=O)N[C@@H]2C(OC[C@@H](C(=O)OC[C@@H](C(=O)OC2)NC(=O)C=2C(=C(O)C=CC=2)O)NC(=O)C=2C(=C(O)C=CC=2)O)=O)=C1O SERBHKJMVBATSJ-BZSNNMDCSA-N 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- 229960000326 flunarizine Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 229940027804 halcion Drugs 0.000 description 1
- 229940095895 haldol Drugs 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960003998 ifenprodil Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 229960004333 indeloxazine Drugs 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 230000008449 language Effects 0.000 description 1
- 208000011977 language disease Diseases 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229940054157 lexapro Drugs 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 229940009622 luvox Drugs 0.000 description 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- KNWQLFOXPQZGPX-UHFFFAOYSA-N methanesulfonyl fluoride Chemical compound CS(F)(=O)=O KNWQLFOXPQZGPX-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000006724 microglial activation Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000004050 mood stabilizer Substances 0.000 description 1
- 229940127237 mood stabilizer Drugs 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 229940065778 narcan Drugs 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000020470 nervous system symptom Diseases 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 230000001962 neuropharmacologic effect Effects 0.000 description 1
- 238000010855 neuropsychological testing Methods 0.000 description 1
- 208000002040 neurosyphilis Diseases 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000000181 nicotinic agonist Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 229940087480 norpramin Drugs 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229940055692 pamelor Drugs 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- ZULJGOSFKWFVRX-UHFFFAOYSA-N pramiracetam Chemical compound CC(C)N(C(C)C)CCNC(=O)CN1CCCC1=O ZULJGOSFKWFVRX-UHFFFAOYSA-N 0.000 description 1
- 229960003389 pramiracetam Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- 229940124811 psychiatric drug Drugs 0.000 description 1
- 229940035677 psycholeptics Drugs 0.000 description 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- SEPKUNXLGWMPHL-UHFFFAOYSA-N quinoxaline-2,3-dione Chemical compound C1=CC=CC2=NC(=O)C(=O)N=C21 SEPKUNXLGWMPHL-UHFFFAOYSA-N 0.000 description 1
- WYJAPUKIYAZSEM-UHFFFAOYSA-N rac-Eburnamonin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(=O)N5C2=C1 WYJAPUKIYAZSEM-UHFFFAOYSA-N 0.000 description 1
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940116246 restoril Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- OBTWBSRJZRCYQV-UHFFFAOYSA-N sulfuryl difluoride Chemical compound FS(F)(=O)=O OBTWBSRJZRCYQV-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940127228 tetracyclic antidepressant Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229940072690 valium Drugs 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229960002922 vinburnine Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940045977 vivactil Drugs 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229940074158 xanax Drugs 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 1
- 229960004141 zuclopenthixol Drugs 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Anesthesiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43637902P | 2002-12-24 | 2002-12-24 | |
| US60/436,379 | 2002-12-24 | ||
| US48221403P | 2003-06-23 | 2003-06-23 | |
| US60/482,214 | 2003-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20050101537A true KR20050101537A (ko) | 2005-10-24 |
Family
ID=32685452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020057012003A Ceased KR20050101537A (ko) | 2002-12-24 | 2003-12-24 | 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20060135403A1 (enExample) |
| EP (2) | EP1585520A1 (enExample) |
| JP (2) | JP2006525226A (enExample) |
| KR (1) | KR20050101537A (enExample) |
| AU (2) | AU2003291910B2 (enExample) |
| BR (1) | BR0317747A (enExample) |
| CA (2) | CA2511599A1 (enExample) |
| EA (1) | EA012325B1 (enExample) |
| IL (1) | IL169338A0 (enExample) |
| MX (1) | MXPA05006940A (enExample) |
| NO (1) | NO20053077L (enExample) |
| NZ (1) | NZ541282A (enExample) |
| WO (2) | WO2004058258A1 (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101443573B1 (ko) * | 2006-10-12 | 2014-11-03 | 비에이치아이 리미티드 파트너쉽 | 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클 |
| WO2018199654A1 (ko) | 2017-04-28 | 2018-11-01 | 강원대학교산학협력단 | 산양삼 추출물을 포함하는 알츠하이머병의 예방 또는 치료용 약학 조성물 |
| KR20200086198A (ko) | 2019-01-08 | 2020-07-16 | 주식회사 솔고 바이오메디칼 | 수소 흡장 금속을 포함하는 치매 예방 또는 치료용 조성물 |
| KR20210133603A (ko) | 2020-04-29 | 2021-11-08 | 정지영 | 굼벵이를 포함하는 치매 예방 또는 치료용 조성물 |
| WO2023200122A1 (ko) * | 2022-04-15 | 2023-10-19 | 아주대학교산학협력단 | Rage 길항제 및 age 소거제를 포함하는 당뇨성 뇌졸중 예방 또는 치료용 약학적 조성물 |
| WO2024128473A1 (ko) * | 2022-12-16 | 2024-06-20 | 닥터노아바이오텍 주식회사 | 콜린에스터라제 억제제의 부작용 예방 또는 치료용 조성물 |
Families Citing this family (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| CN100444840C (zh) | 2003-05-15 | 2008-12-24 | 罗斯坎普研究有限公司 | 减少淀粉样沉积、淀粉样神经毒性和小胶质增生的药物 |
| WO2005000288A2 (en) * | 2003-06-23 | 2005-01-06 | Neurochem (International) Limited | Treatment of protein aggregation disorders |
| US20070010573A1 (en) | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| US20050142191A1 (en) * | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| CA2529257C (en) * | 2003-06-23 | 2013-04-23 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| AU2011250847B2 (en) * | 2003-06-23 | 2013-06-20 | Bhi Limited Partnership | Methods and compositions for treating amyloid-related diseases |
| KR20110140139A (ko) * | 2003-08-29 | 2011-12-30 | 오노 야꾸힝 고교 가부시키가이샤 | Ｓ１ｐ 수용체 결합능을 갖는 화합물 및 그 의약 용도 |
| AR047062A1 (es) | 2003-12-17 | 2006-01-04 | Wyeth Corp | Conjugados portadores de peptidos inmunogenicos a beta y metodos para producirlos |
| MXPA06011969A (es) * | 2004-04-14 | 2006-12-15 | Warner Lambert Co | Combinacion terapeutica para tratamiento de la enfermedad de alzheimer. |
| CA2582385A1 (en) * | 2004-06-18 | 2005-12-18 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| JP4717537B2 (ja) * | 2004-08-31 | 2011-07-06 | 株式会社 資生堂 | 皮膚外用組成物 |
| EP1828111A2 (en) * | 2004-11-12 | 2007-09-05 | Neurochem (International) Limited | Methods and fluorinated compositions for treating amyloid-related diseases |
| JP5145537B2 (ja) * | 2004-12-22 | 2013-02-20 | ビーエイチアイ リミテッド パートナーシップ | アミロイド関連疾患を治療するための方法および組成物 |
| TW200716088A (en) * | 2005-04-15 | 2007-05-01 | Neurochem Int Ltd | Formulations and methods for treating amyloidosis |
| US7420071B2 (en) * | 2005-05-04 | 2008-09-02 | Uchicago Argonne, Llc | Thermally stable surfactants and compositions and methods of use thereof |
| CN117903302A (zh) | 2005-11-30 | 2024-04-19 | Abbvie 公司 | 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法 |
| PT1976877E (pt) | 2005-11-30 | 2014-04-29 | Abbvie Inc | Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações |
| ES2454253T3 (es) | 2005-12-12 | 2014-04-10 | Ac Immune S.A. | Anticuerpos monoclonales específicos de beta A 1-42 con propiedades terapéuticas |
| MY181173A (en) | 2005-12-12 | 2020-12-21 | Ac Immune Sa | Therapeutic vaccine |
| DE602006016990D1 (de) | 2005-12-22 | 2010-10-28 | Bellus Health Int Ltd | Behandlung von diabetischer nephropathie |
| WO2007084818A2 (en) * | 2006-01-10 | 2007-07-26 | Pipex, Inc. | Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases |
| KR101605207B1 (ko) | 2006-07-14 | 2016-03-22 | 에이씨 이뮨 에스.에이. | 아밀로이드 베타에 대해 인간화된 항체 |
| CN103524617B (zh) | 2006-07-14 | 2016-12-28 | Ac免疫有限公司 | 针对淀粉状蛋白β的人源化抗体 |
| WO2008070284A2 (en) | 2006-10-16 | 2008-06-12 | Johnnie B. Byrd, Sr. Alzheimer's Center And Research Institute | Amyloid beta peptides and methods of uses thereof |
| KR101450356B1 (ko) | 2006-11-24 | 2014-10-15 | 에이씨 이뮨 에스.에이. | 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체 |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| GB0701970D0 (en) * | 2007-02-01 | 2007-03-14 | Wilson Stuart | Treatment of protein aggregation diseases |
| US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| WO2008106657A2 (en) * | 2007-03-01 | 2008-09-04 | Intezyne Technologies, Inc. | Encapsulated amyloid-beta peptides |
| EP2160352A2 (en) * | 2007-05-24 | 2010-03-10 | Simone Arca | Method for the production of binary clathrate hydrates of hydrogen |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| AR066987A1 (es) | 2007-06-12 | 2009-09-23 | Ac Immune Sa | Anticuerpo monoclonal contra proteina beta-amiloide |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| PL2170389T3 (pl) | 2007-06-12 | 2015-03-31 | Ac Immune Sa | Humanizowane przeciwciało przeciw amyloidowi beta |
| AU2008280782B2 (en) * | 2007-07-20 | 2014-01-23 | Diamedica Inc. | Tissue kallikrein for the treatment of diseases associated with amyloid protein |
| EP2044951A1 (en) | 2007-10-02 | 2009-04-08 | Merz Pharma GmbH & Co. KGaA | The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases |
| RU2571859C2 (ru) | 2007-10-05 | 2015-12-20 | Дженентек, Инк. | Применение антитела против амилоида-бета при глазных заболеваниях |
| ES2445590T3 (es) | 2007-10-05 | 2014-03-04 | Genentech, Inc. | Uso de anticuerpo anti-amiloide beta en enfermedades oculares |
| BRPI0817516A2 (pt) | 2007-10-05 | 2015-06-16 | Alzheimer S Inst Of America Inc | Método para reduzir deposição de amilóide, neurotoxicidade de amilóide e microgliose com o enantiômero de (-)-nilvadipino |
| WO2009059239A2 (en) * | 2007-11-02 | 2009-05-07 | Mayo Foundation For Medical Education And Research | REDUCING Aβ42 LEVELS AND Aβ AGGREGATION |
| EP2149380A1 (en) * | 2008-07-29 | 2010-02-03 | Medivet Pharma, S.L. | Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction. |
| US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
| WO2010042603A1 (en) * | 2008-10-08 | 2010-04-15 | Cingulate Neuro Therapeutics, Llc | Amyloid and depression |
| PT2408807T (pt) | 2009-03-18 | 2021-09-03 | Ac Immune Sa | Processo para utilização terapêutica |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| JP5051274B2 (ja) | 2009-06-04 | 2012-10-17 | 住友化学株式会社 | 加硫ゴムが有する粘弾性特性を改善させるためのｓ−（３−アミノプロピル）チオ硫酸および／またはその金属塩の使用 |
| EP2311823A1 (en) | 2009-10-15 | 2011-04-20 | AC Immune S.A. | 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases |
| CN104744591B (zh) | 2010-04-15 | 2022-09-27 | Abbvie德国有限责任两合公司 | β淀粉样蛋白结合蛋白 |
| EP2377860A1 (en) | 2010-04-16 | 2011-10-19 | AC Immune S.A. | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| DK2558446T5 (da) | 2010-04-16 | 2019-12-09 | Ac Immune Sa | Nye forbindelser til behandling af sygdomme associerede med amyloid- eller amyloidlignende proteiner |
| US9221900B2 (en) | 2010-07-30 | 2015-12-29 | Ac Immune S.A. | Methods for identifying safe and functional humanized antibodies |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| HUE027649T2 (en) | 2010-10-07 | 2016-10-28 | Ac Immune Sa | Antibodies recognising phospho-tau |
| WO2012055933A1 (en) | 2010-10-26 | 2012-05-03 | Ac Immune S.A. | Liposome-based construct comprising a peptide modified through hydrophobic moieties |
| US20120321694A1 (en) * | 2010-10-27 | 2012-12-20 | Daniel Larocque | Compositions and uses |
| MA34828B1 (fr) | 2011-01-10 | 2014-01-02 | Zinfandel Pharmaceuticals Inc | Procédés et produits médicamenteux destinés au traitement de la maladie d'alzheimer |
| US9499488B2 (en) * | 2011-07-11 | 2016-11-22 | Beth Israel Deaconess Medical Center, Inc. | Vitamin D receptor agonists and uses thereof |
| KR20160099732A (ko) | 2011-09-23 | 2016-08-22 | 에이씨 이뮨 에스.에이. | 백신 요법 |
| BR112014008202B1 (pt) | 2011-10-07 | 2022-01-04 | Ac Immune S.A. | Anticorpo, polinucleotídeo, composição farmacêutica, usos de um anticorpo, método in vitro, método de detecção da formação de um complexo imunológico, método de detecção postmortem de multimêros do fosfo-tau, kits de teste, linhagem celular isolada e método de detecção de multimêros de fosfo-tau |
| KR102132041B1 (ko) | 2012-04-05 | 2020-07-09 | 에이씨 이뮨 에스.에이. | 인간화된 타우 항체 |
| US20130315891A1 (en) | 2012-05-25 | 2013-11-28 | Matthew Charles | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
| HUE032613T2 (en) | 2012-06-04 | 2017-10-30 | Diamedica Therapeutics Inc | Human tissue kallikrein 1 is glycosylated isoforms |
| WO2014025761A1 (en) * | 2012-08-07 | 2014-02-13 | Children's Medical Center Corporation | Methods to treat neurodegenerative diseases |
| PE20151026A1 (es) * | 2012-12-13 | 2015-07-11 | Lundbeck & Co As H | Composiciones que comprenden vortioxetina y donepezilo |
| US9200068B2 (en) * | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
| JP6568514B2 (ja) | 2013-03-15 | 2019-08-28 | エーシー イミューン エス．エー． | 抗タウ抗体及び使用方法 |
| US10662193B2 (en) | 2014-01-21 | 2020-05-26 | Ac Immune Sa | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins |
| US10314911B2 (en) * | 2014-04-08 | 2019-06-11 | Healthpartners Research & Education | Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin |
| US9814712B2 (en) * | 2014-05-09 | 2017-11-14 | Tecnimede Sociedade Tecnico-Medicinal S.A. | (S)-pirlindole and its pharmaceutically acceptable salts for use in medicine |
| MA39448B1 (fr) * | 2014-05-09 | 2019-12-31 | Tecnimede Sociedade Tecnico Medicinal S | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical |
| CN107428820B (zh) | 2014-11-19 | 2022-03-22 | 阿克松神经系统科学公司 | 在阿尔茨海默氏病中的人源化tau抗体 |
| JP6793134B2 (ja) | 2015-06-05 | 2020-12-02 | ジェネンテック， インコーポレイテッド | 抗ｔａｕ抗体及び使用方法 |
| MX380290B (es) | 2015-08-10 | 2025-03-12 | Alzheon Inc | Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos. |
| EP3374379A4 (en) | 2015-11-09 | 2019-05-15 | The University Of British Columbia | N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATION-SELECTIVE ANTIBODIES |
| AU2016354688B2 (en) | 2015-11-09 | 2021-12-16 | The University Of British Columbia | Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto |
| HK1259324A1 (zh) | 2015-11-09 | 2019-11-29 | 英属哥伦比亚大学 | 淀粉样蛋白β表位及其抗体 |
| ITUA20161679A1 (it) | 2016-03-15 | 2017-09-15 | Neuraxpharm Italy S P A | Composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi |
| KR102550991B1 (ko) | 2016-07-18 | 2023-07-04 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타에 대한 항체 |
| WO2018038973A1 (en) * | 2016-08-20 | 2018-03-01 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Neuroprotective beta amyloid core peptides and peptidomimetic derivatives |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| MY198942A (en) | 2016-12-07 | 2023-10-03 | Genentech Inc | Anti-tau antibodies and methods of use |
| CN110248959B (zh) | 2016-12-07 | 2023-06-30 | 基因泰克公司 | 抗tau抗体和使用方法 |
| KR20190122706A (ko) | 2017-03-09 | 2019-10-30 | 다이어메디카 인코포레이티드 | 조직 칼리크레인 1의 투약 형태 |
| EP3601337A1 (en) | 2017-03-28 | 2020-02-05 | Genentech, Inc. | Methods of treating neurodegenerative diseases |
| CA3061340A1 (en) | 2017-04-25 | 2018-11-01 | Temple Otorongo Llc | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions |
| WO2019018445A1 (en) * | 2017-07-17 | 2019-01-24 | Maxwell Biosciences, Inc. | POLYTHERAPY MODULATING THE MODULATION OF CATHELICIDINE GENE EXPRESSION FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISEASES |
| US12286469B2 (en) | 2017-07-18 | 2025-04-29 | The University Of British Columbia | Humanized antibodies binding to amyloid-beta (A-beta) |
| WO2019074840A1 (en) * | 2017-10-09 | 2019-04-18 | Keith Black | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOID RELATED DISEASES |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| TWI827557B (zh) | 2017-10-25 | 2024-01-01 | 美商健生醫藥公司 | Ｔａｕ胜肽之組成物及其用途 |
| BR112020012833A2 (pt) | 2018-01-05 | 2021-01-05 | Ac Immune Sa. | Derivados de 1, 3, 4, 5-tetra-hidro-2h-pirido[4,3-b]indol para o tratamento, alívio ou prevenção de distúrbios associados com agregados de tau, como doença de alzheimer |
| RU2020135052A (ru) | 2018-03-28 | 2022-04-29 | Аксон Ньюросайенс Се | Способы выявления и лечения болезни альцгеймера на основе антител |
| MX2020013115A (es) | 2018-06-04 | 2021-05-12 | Ac Immune Sa | Compuestos de tetrahidrobenzofuro[2,3-c]piridina y beta-carbolina para el tratamiento, el alivio o la prevencion de trastornos asociados con los agregados de tau. |
| CN112313230B (zh) | 2018-06-04 | 2024-03-15 | Ac免疫有限公司 | 用于治疗、缓解或预防与Tau聚集体相关的病症的新型化合物 |
| US20200222400A1 (en) * | 2019-01-16 | 2020-07-16 | Yumanity Therapeutics, Inc. | Methods for the treatment of neurological disorders |
| EP3920966A2 (en) | 2019-02-08 | 2021-12-15 | AC Immune S.A. | Method of safe administration of phosphorylated tau peptide vaccine |
| CN113453688A (zh) | 2019-03-01 | 2021-09-28 | Ac免疫有限公司 | 用于治疗、减轻或预防与Tau聚集体相关的病症的新化合物 |
| JP2022529353A (ja) | 2019-04-17 | 2022-06-21 | コンパス パスファインダー リミテッド | 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法 |
| JP7327788B2 (ja) * | 2019-08-06 | 2023-08-16 | 学校法人福岡大学 | 糖化産物生成抑制剤及び医薬組成物 |
| WO2021055670A1 (en) | 2019-09-20 | 2021-03-25 | Avx Corporation | Somatic cell-based electrical biosensor |
| WO2021067850A2 (en) * | 2019-10-02 | 2021-04-08 | Washington University | METHODS OF DETECTING circRNA |
| ES2821599A1 (es) | 2019-10-24 | 2021-04-26 | Univ Del Pais Vasco / Euskal Herriko Unibertsitatea | Compuestos y metodos para el tratamiento de la enfermedad de alzheimer |
| CN112939823A (zh) * | 2019-12-10 | 2021-06-11 | 中国石油天然气股份有限公司 | 泥页岩抑制剂制备方法及抑制剂的应用 |
| US20210353566A1 (en) * | 2020-05-12 | 2021-11-18 | Massachusetts Institute Of Technology | The use of choline supplementation as therapy for apoe4-related disorders |
| AR123730A1 (es) | 2020-10-15 | 2023-01-04 | Ac Immune Sa | Compuestos novedosos |
| JP7682515B2 (ja) * | 2020-12-11 | 2025-05-26 | 国立研究開発法人国立長寿医療研究センター | 認知症の危険性判定システムおよび認知症の危険性判定用プログラム |
| JP2024534151A (ja) | 2021-08-27 | 2024-09-18 | ジェネンテック， インコーポレイテッド | タウ病態の治療方法 |
| CN115624555A (zh) * | 2022-02-24 | 2023-01-20 | 中国药科大学 | 猪去氧胆酸在制备抗抑郁药物中的应用 |
| KR20240162497A (ko) | 2022-03-14 | 2024-11-15 | 제넨테크, 인크. | 음성 분석에 기반한 신경퇴행성 질환 예측 |
| CN119404251A (zh) | 2022-06-21 | 2025-02-07 | 基因泰克公司 | 基于言语分析检测阿尔茨海默病(ad)的纵向进展 |
| CN119570766B (zh) * | 2025-02-08 | 2025-05-16 | 上海锴泰生物科技有限公司 | 一种胶原蛋白酶突变体、基因片段、重组质粒、重组表达体系、胶原蛋白肽，及其制备方法和用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| ATE311864T1 (de) * | 1993-03-29 | 2005-12-15 | Propan-1,3-disulphonsäure und deren pharmazeutisch akzeptable salze zur behandlung von amyloidosis | |
| WO1997021728A1 (en) * | 1995-12-12 | 1997-06-19 | Karolinska Innovations Ab | PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b) |
| JPH10259126A (ja) * | 1997-01-17 | 1998-09-29 | Takeda Chem Ind Ltd | アルツハイマー病治療・予防剤 |
| ES2392391T3 (es) * | 1998-02-11 | 2012-12-10 | Bhi Limited Partnership | Método para modular la activación de macrófagos |
| GB9805561D0 (en) * | 1998-03-16 | 1998-05-13 | Merck Sharp & Dohme | A combination of therapeutic agents |
| MXPA00011213A (es) * | 1998-05-15 | 2003-04-22 | Neurochem Inc | Uso de inhibidores de amiloides para la modulacion de la muerte de las celulas neuronales. |
| BR0008738A (pt) * | 1999-03-04 | 2001-12-26 | Praecis Pharm Inc | Moduladores de agregação de peptìdeobeta-amilóide compreendendo d-aminoácidos |
| JP4726304B2 (ja) * | 1999-04-28 | 2011-07-20 | ベルス ヘルス （インターナショナル） リミティッド | アミロイドーシスを治療するための組成物および方法 |
| JP2003503312A (ja) * | 1999-05-05 | 2003-01-28 | ニューロシェム インコーポレイテッド | 立体選択的抗原線維形成ペプチドおよびそのペプチド模倣体 |
| US20020094335A1 (en) * | 1999-11-29 | 2002-07-18 | Robert Chalifour | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
| BR0016652A (pt) * | 1999-12-23 | 2002-11-19 | Neurochem Inc | Métodos para inibir angiopatia amilóide cerebral, para tratar um estado de doença caracterizado por angiopatia amilóide cerebral em um indivìduo, e para diagnosticar angiopatia amilóide cerebral em um indivìduo |
| US20020151591A1 (en) * | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| US20040072753A1 (en) * | 2000-11-01 | 2004-04-15 | Milton Nathaniel Gavin Nicolas | Peptides for use in the treatment of alzheimer's disease |
| US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20050142191A1 (en) * | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| US7253306B2 (en) * | 2003-06-23 | 2007-08-07 | Neurochem (International) Limited | Pharmaceutical drug candidates and methods for preparation thereof |
| US20050038000A1 (en) * | 2003-06-23 | 2005-02-17 | Xianqi Kong | Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases |
-
2003
- 2003-12-24 EA EA200501023A patent/EA012325B1/ru not_active IP Right Cessation
- 2003-12-24 WO PCT/CA2003/002011 patent/WO2004058258A1/en not_active Ceased
- 2003-12-24 WO PCT/CA2003/002021 patent/WO2004058239A1/en not_active Ceased
- 2003-12-24 US US10/540,763 patent/US20060135403A1/en not_active Abandoned
- 2003-12-24 EP EP03767368A patent/EP1585520A1/en not_active Withdrawn
- 2003-12-24 MX MXPA05006940A patent/MXPA05006940A/es active IP Right Grant
- 2003-12-24 JP JP2005509680A patent/JP2006525226A/ja not_active Withdrawn
- 2003-12-24 AU AU2003291910A patent/AU2003291910B2/en not_active Ceased
- 2003-12-24 NZ NZ541282A patent/NZ541282A/en unknown
- 2003-12-24 AU AU2003292936A patent/AU2003292936A1/en not_active Abandoned
- 2003-12-24 JP JP2005509679A patent/JP2006512417A/ja active Pending
- 2003-12-24 CA CA002511599A patent/CA2511599A1/en not_active Abandoned
- 2003-12-24 KR KR1020057012003A patent/KR20050101537A/ko not_active Ceased
- 2003-12-24 EP EP03788737A patent/EP1581203A1/en not_active Withdrawn
- 2003-12-24 BR BR0317747-5A patent/BR0317747A/pt not_active IP Right Cessation
- 2003-12-24 CA CA002511606A patent/CA2511606A1/en not_active Abandoned
-
2005
- 2005-06-22 IL IL169338A patent/IL169338A0/en unknown
- 2005-06-23 NO NO20053077A patent/NO20053077L/no not_active Application Discontinuation
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101443573B1 (ko) * | 2006-10-12 | 2014-11-03 | 비에이치아이 리미티드 파트너쉽 | 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클 |
| WO2018199654A1 (ko) | 2017-04-28 | 2018-11-01 | 강원대학교산학협력단 | 산양삼 추출물을 포함하는 알츠하이머병의 예방 또는 치료용 약학 조성물 |
| KR20200086198A (ko) | 2019-01-08 | 2020-07-16 | 주식회사 솔고 바이오메디칼 | 수소 흡장 금속을 포함하는 치매 예방 또는 치료용 조성물 |
| KR20210133603A (ko) | 2020-04-29 | 2021-11-08 | 정지영 | 굼벵이를 포함하는 치매 예방 또는 치료용 조성물 |
| WO2023200122A1 (ko) * | 2022-04-15 | 2023-10-19 | 아주대학교산학협력단 | Rage 길항제 및 age 소거제를 포함하는 당뇨성 뇌졸중 예방 또는 치료용 약학적 조성물 |
| WO2024128473A1 (ko) * | 2022-12-16 | 2024-06-20 | 닥터노아바이오텍 주식회사 | 콜린에스터라제 억제제의 부작용 예방 또는 치료용 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003291910B2 (en) | 2009-10-01 |
| AU2003291910A1 (en) | 2004-07-22 |
| EP1581203A1 (en) | 2005-10-05 |
| WO2004058239A1 (en) | 2004-07-15 |
| NO20053077D0 (no) | 2005-06-23 |
| MXPA05006940A (es) | 2006-02-22 |
| US20060135403A1 (en) | 2006-06-22 |
| JP2006512417A (ja) | 2006-04-13 |
| CA2511599A1 (en) | 2004-07-15 |
| NZ541282A (en) | 2009-02-28 |
| EA012325B1 (ru) | 2009-08-28 |
| BR0317747A (pt) | 2005-11-22 |
| JP2006525226A (ja) | 2006-11-09 |
| AU2003292936A1 (en) | 2004-07-22 |
| WO2004058258A1 (en) | 2004-07-15 |
| IL169338A0 (en) | 2007-07-04 |
| CA2511606A1 (en) | 2004-07-15 |
| EA200501023A1 (ru) | 2005-12-29 |
| EP1585520A1 (en) | 2005-10-19 |
| NO20053077L (no) | 2005-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20050101537A (ko) | 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제 | |
| US20050031651A1 (en) | Therapeutic formulations for the treatment of beta-amyloid related diseases | |
| JP2008504372A (ja) | β−アミロイド関連疾患の治療のための治療用製剤 | |
| ES2275007T3 (es) | Uso de derivados de azetidinona sustitudos en el tratamiento de la enfermedad de alzeimer. | |
| CN100571701C (zh) | 治疗β淀粉样蛋白相关疾病的治疗性制品 | |
| DE60224163T2 (de) | Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen | |
| JP4614460B2 (ja) | シトステロール血症の処置のための置換アゼチジノン化合物の使用 | |
| US7244749B2 (en) | Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases | |
| US20170042878A1 (en) | Compositions comprising scopolamine and ketamine in the treatment of depression | |
| SK281173B6 (sk) | Použitie kombinácie beta-laktámového inhibítora absorpcie cholesterolu s inhibítorom biosyntézy cholesterolu, farmaceutický prostriedok a súprava s ich obsahom | |
| JP5770173B2 (ja) | 認知疾患、障害または病態の治療、症状緩和、軽減、改善および予防方法 | |
| JP2008514718A (ja) | 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ | |
| JP2006508188A (ja) | 脱髄の処置のためのコレステロール吸収インヒビター | |
| JP2009517393A (ja) | 不安症の治療方法 | |
| CN108463224A (zh) | sGC刺激剂用于胃肠功能障碍治疗的应用 | |
| CN109476686B (zh) | sGC刺激剂的磷前药 | |
| ZA200507439B (en) | Use of carbamazepine derivatives for the treatment of agitation in dementia patients | |
| HRP960341A2 (en) | New methods of using n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters) | |
| UA82480C2 (uk) | Застосування комбінації донепезилу та мемантину для лікування хвороби альцгеймера | |
| HK1168005B (en) | Methods for preventing and/or treating degenerative disorders of the central nervous system | |
| MX2013001354A (es) | Composicion farmaceutica oral que contiene una combinacion de un relajante del musculo liso visceral y un analgesico/anti-inflamato rio, y su uso en el tratamiento del sindrome de colon irritable de etiologia diversa. | |
| HK1168005A1 (zh) | 用於預防和/或治療中樞神經系統退行性紊亂的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20050624 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20081218 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20101105 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20110221 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20101105 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |